Active immunotherapy of stage IV renal cell cancer using autologous tumor cells

1986 ◽  
Vol 3 (4) ◽  
pp. 245-248 ◽  
Author(s):  
T. Sch�rfe ◽  
E. Becht ◽  
K. F. Klippel ◽  
G. H. Jacobi ◽  
R. Hohenfellner
2003 ◽  
Vol 21 (5) ◽  
pp. 884-890 ◽  
Author(s):  
Alfred E. Chang ◽  
Qiao Li ◽  
Guihua Jiang ◽  
Donna M. Sayre ◽  
Thomas M. Braun ◽  
...  

Purpose: Previous preclinical and clinical studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reactive T cells in draining lymph nodes. The adoptive transfer of these cells can result in tumor regression. Patients and Methods: Patients with stage IV renal cell cancer (RCC) were vaccinated with irradiated autologous tumor cells admixed with Calmette-Guérin bacillus. Approximately 7 days later, vaccine-primed lymph nodes (VPLNs) were harvested and the lymphoid cells secondarily activated with anti-CD3 monoclonal antibody and expanded in interleukin 2 (IL-2). The activated cells were subsequently infused intravenously along with the concomitant administration of bolus IL-2 (360,000 U/kg intravenously × 15 doses). Results: Thirty-nine patients were entered onto the study, of whom 34 completed an initial course of cell therapy consisting of a mean (SEM) number of 4.3 (2.2) × 1010 VPLN cells. Among subjects who received cell therapy, there were nine responses (four complete responses [CRs] and five partial responses [PRs]), for an overall response rate of 27%. The durations of the CRs were > 48, 45, > 35, and 12 months, and the durations of the PRs were > 63, 48, 15, 12, and 4 months. Cultured tumor cells were available to assess in vitro cytokine release of VPLN cells in 24 subjects. The median cytokine release ratio of interferon gamma (IFNγ) to IL-10 for responders and nonresponders was 992 and 5, respectively, which was significantly different (P = .047). Conclusion: The treatment protocol resulted in durable tumor responses in patients with advanced RCC. The ratio of IFNγ and IL-10 cytokines released in response to tumor by the VPLN cells was a significant correlate with tumor response.


2004 ◽  
Vol 10 (4) ◽  
pp. 799-816 ◽  
Author(s):  
Kenzaburo Tani ◽  
Miyuki Azuma ◽  
Yukoh Nakazaki ◽  
Naoki Oyaizu ◽  
Hidenori Hase ◽  
...  

1997 ◽  
Vol 36 (2) ◽  
pp. 228-228 ◽  
Author(s):  
Giovanni Citterio ◽  
Giuseppe Di Lucca ◽  
Ugo Scaglietti ◽  
Sara Gilberti ◽  
Monica Baldini ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1580-1580
Author(s):  
Ana Beatriz Sanchez-Heras ◽  
Adela Castillejo ◽  
Juan de Dios García-Diaz ◽  
Mercedes Robledo ◽  
Alex Teule ◽  
...  

1580 Background: HLRCC is a hereditary condition with autosomal dominant inheritance due to germline mutations in the fumarate-hydratase gene ( FH). It is characterized by skin leiomyomas (SLM) in 48-84% of individuals, uterine leiomyomas (ULM) in 30-72%, renal cysts (RCy) and renal cell cancer (RCC) in 15-34%. We aimed to describe the genetics, the clinical features and the potential genotype-phenotype associations in the largest cohort of FH mutation carriers from Spain. Methods: We performed a multicenter, observational, retrospective study of individuals with genetic or clinical diagnosis of HLRCC. We collected clinical information from medical records. We analyzed genetic variants and looked for genotype-phenotype associations. Statistical analyses were performed by IBM-SPSS Statistics-v.22. Results: We included 197 individuals (113 women, 84 men), 74 index cases and 123 relatives. Twenty-seven different variants were detected, 26 pathogenic (12 missense, 5 frameshift, 4 large-deletions, 3 splice-site and 2 nonsense) and 1 variant of unknown significance (missense). Of 182 patients with full skin examination, 64.8% presented SLM (median age 36 years; range 8-85). ULM were diagnosed in 90.3% of 103 women with gynecologic exam (median age 30 years; range 17- 55). Hysterectomy was performed in 62.9% (median age 34 years; range 21-54). Of 153 patients with radiological records, 37.3 % presented RCy. Nineteen patients (10.9%) presented RCC, 11 males and 8 females (median age 37 years; range 10-67). The histological diagnoses were: 14 papillary, of which 10 were type 2; 3 clear cell carcinoma and 2 unclassified carcinoma. Six tumors had stage I, 2 stage II, 3 stage III, 4 stage IV, and 4 not available. The median overall survival among patients at stages 3-4 was 2.9 years [1.3-4.5]. Patients with missense pathogenic variants showed higher risk of developing SLM (p = 0.043) and ULM (p = 0.002) than those with loss of function variants. Conclusions: In our cohort, the frequency of RCC (10.9%) is lower than that published in cohorts of similar sample size. The most frequent histology was the papillary type-2; however, other histological patterns do not exclude HLRCC. Individuals with missense pathogenic variants show higher incidence of SLM and ULM.


2020 ◽  
Vol 9 (5) ◽  
pp. 1372
Author(s):  
Petr Klezl ◽  
Eliska Pospisilova ◽  
Katarina Kolostova ◽  
Jindrich Sonsky ◽  
Ondrej Maly ◽  
...  

The presence of circulating tumor cells (CTCs) in patients with solid tumors is associated with poor prognosis. However, there are limited data concerning the detection of CTCs in renal cell cancer (RCC). The aim of this study is to evaluate the presence of CTCs in peripheral blood of patients with RCC undergoing surgery (n = 186). CTCs were tested before and after surgery as well as during the follow-up period afterwards. In total 495 CTC testing in duplicates were provided. To enrich CTCs, a size-based separation protocol and tube MetaCell® was used. CTCs presence was evaluated by single cell cytomorphology based on vital fluorescence microscopy. Additionally, to standardly applied fluorescence stains, CTCs viability was controlled by mitochondrial activity. CTCs were detected independently on the sampling order in up to 86.7% of the tested blood samples in patients undergoing RCC surgery. There is higher probability of CTC detection with growing tumor size, especially in clear cell renal cell cancer (ccRCC) cases. Similarly, the tumor size corresponds with metastasis presence and lymph node positivity and CTC detection. This paper describes for the first-time successful analysis of viable CTCs and their mitochondria as a part of the functional characterization of CTCs in RCC.


2018 ◽  
Vol 11 (1) ◽  
pp. 38-42 ◽  
Author(s):  
Muna Ferner ◽  
Andrea Vera Keck ◽  
Dora Niedersüß-Beke ◽  
Kathrin Strasser-Weippl

Gene Therapy ◽  
2010 ◽  
Vol 18 (4) ◽  
pp. 354-363 ◽  
Author(s):  
J Westermann ◽  
A Flörcken ◽  
G Willimsky ◽  
A van Lessen ◽  
J Kopp ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document